Roche: positive two-year data for Elevidys
(CercleFinance.com) - Roche reports first positive results from the second year of EMBARK, a Phase III study of Elevidys, the first gene therapy approved for the treatment of people with Duchenne muscular dystrophy.
Statistically and clinically significant improvements were observed in three key measures of motor function (North Star ambulatory assessment, climbing time and 10-meter walk/run), compared with an untreated external control group.
Functional differences between Elevidys-treated individuals and those in the external control group increased between one and two years after administration. Taken together, these results demonstrate a consistent and sustained benefit for Elevidys.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Statistically and clinically significant improvements were observed in three key measures of motor function (North Star ambulatory assessment, climbing time and 10-meter walk/run), compared with an untreated external control group.
Functional differences between Elevidys-treated individuals and those in the external control group increased between one and two years after administration. Taken together, these results demonstrate a consistent and sustained benefit for Elevidys.
Copyright (c) 2025 CercleFinance.com. All rights reserved.